<main class="detailed-guide" lang="en" role="main">
      
<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Orphan medicinal products
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">The MHRA will review applications for orphan designation at the time of a marketing authorisation (MA) or variation application.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div lang="en" class="app-c-publisher-metadata">
    <div lang="en" class="app-c-published-dates ">
    Published 31 December 2020
    <br>Last updated 22 February 2021
      — <a href="#history" class="app-c-published-dates__history-link govuk-link">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>





<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div data-module="sticky-element-container" class="app-c-contents-list-with-body">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " data-module="track-click" role="navigation" aria-label="Contents">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-label="#application-process" href="#application-process" data-track-action="content_item 1" data-track-options="{&quot;dimension29&quot;:&quot;Application process&quot;}" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link ">Application process</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a href="#how-to-apply" data-track-label="#how-to-apply" class="gem-c-contents-list__link govuk-link " data-track-options="{&quot;dimension29&quot;:&quot;How to apply&quot;}" data-track-category="contentsClicked" data-track-action="content_item 2">How to apply</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-label="#market-exclusivity-period" data-track-options="{&quot;dimension29&quot;:&quot;Market exclusivity period&quot;}" data-track-action="content_item 3" class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" href="#market-exclusivity-period">Market exclusivity period</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a href="#paediatric-indications" class="gem-c-contents-list__link govuk-link " data-track-options="{&quot;dimension29&quot;:&quot;Paediatric indications&quot;}" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#paediatric-indications">Paediatric indications</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#review-of-market-exclusivity-period" data-track-options="{&quot;dimension29&quot;:&quot;Review of market exclusivity period&quot;}" class="gem-c-contents-list__link govuk-link " href="#review-of-market-exclusivity-period">Review of market exclusivity period</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a data-track-action="content_item 6" data-track-label="#variation-applications-section-41-of-the-summary-of-products-characteristics" href="#variation-applications-section-41-of-the-summary-of-products-characteristics" class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-options="{&quot;dimension29&quot;:&quot;Variation applications (section 4.1 of the Summary of Products Characteristics)&quot;}">Variation applications (section 4.1 of the Summary of Products Characteristics)</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" href="#fees" data-track-action="content_item 7" data-track-label="#fees" data-track-options="{&quot;dimension29&quot;:&quot;Fees&quot;}">Fees</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-label="#sme-status" data-track-options="{&quot;dimension29&quot;:&quot;\nSME status&quot;}" href="#sme-status" data-track-category="contentsClicked" data-track-action="content_item 8">
SME status</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-options="{&quot;dimension29&quot;:&quot;Orphan register&quot;}" data-track-action="content_item 9" data-track-category="contentsClicked" data-track-label="#orphan-register" href="#orphan-register">Orphan register</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 10" href="#contact" data-track-label="#contact" data-track-options="{&quot;dimension29&quot;:&quot;Contact&quot;}">Contact</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link gem-c-print-link__button">Print this page</button>
</div>

      
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
        <div class="govspeak">
<p>The MHRA offers incentives in the form of market exclusivity and full or partial refunds for marketing authorisation fees to encourage the development of medicines in rare diseases. Waiver from scientific advice fees will also be available for UK based <abbr title="small and medium sized enterprises">SMEs</abbr>.</p>

<p>See the <a class="govuk-link" href="http://www.gov.uk/government/publications/rare-diseases-strategy">UK Rare diseases strategy</a> for other supportive activities.</p>

<h2>Application process</h2>

<p>The MHRA is responsible for reviewing applications from companies for orphan designation at the time of a marketing authorisation application (<abbr title="marketing authorisation application">MAA</abbr>).</p>

<p>There is no pre-marketing authorisation orphan designation.</p>

<p>Products with an orphan designation in the EU can be considered for a Great Britain orphan marketing authorisation (MA). In accordance with Regulation 50G of the Human Medicines Regulation 2012 (as amended), a UK-wide orphan marketing authorisation can only be considered in the absence of an active EU orphan designation.</p>

<p>If a UK-wide orphan marketing authorisation is granted and the medicinal product subsequently receives EU orphan designation, the market authorisation holder (MAH) would need to submit a variation to change this to a Great Britain orphan MA.</p>

<p>To qualify for orphan designation in an orphan condition, a medicine must meet the following criteria:</p>

<ul>
  <li>
    <p>it must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating</p>
  </li>
  <li>
    <p>the prevalence of the condition in Great Britain must not be more than 5 in 10,000, or it must be unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development</p>
  </li>
  <li>
    <p>no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists in Great Britain, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition</p>

    <ul>
      <li>Satisfactory methods may include authorised medicinal products, medical devices or other methods of diagnosis, prevention or treatment which are used in Great Britain.</li>
    </ul>
  </li>
</ul>

<h2>How to apply</h2>

<p>Marketing Authorisation Applicants should submit the <span class="attachment-inline"><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/949023/GB_Orphan_Drug_Application_Form.docx" class="govuk-link">Great Britain Orphan Drug Designation Application Form</a> (<span class="type">MS Word Document</span>, <span class="file-size">831KB</span>)</span> with their <abbr title="marketing authorisation application">MAA</abbr> in module 1.2 of the eCTD, specifically indicating in the cover letter their intention to seek an orphan designation.</p>

<p>Applications for orphan designation will be examined by the MHRA’s advisory committee, the <a class="govuk-link" href="https://www.gov.uk/government/organisations/commission-on-human-medicines">Commission on Human Medicines (<abbr title="Commission on Human Medicines">CHM</abbr>)</a>. A decision on fulfilment of the orphan criteria runs in parallel with the assessment of the marketing authorisation procedure.</p>

<p>Following the validation of the <abbr title="marketing authorisation application">MAA</abbr>, a decision on orphan status will be made at the time of the decision on approval of the marketing authorisation (see guidance on <a class="govuk-link" href="https://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk">new assessment procedures</a>). Any questions concerning the fulfilment of the orphan designation criteria will be raised with the company during the evaluation of the <abbr title="marketing authorisation application">MAA</abbr>.</p>

<p>If the MHRA concludes that the criteria for orphan designation are not met, there will be an opportunity to appeal the decision to the <abbr title="Commission on Human Medicines">CHM</abbr> before the MA is granted. The applicant should inform the MHRA of the intention to appeal as soon as possible.</p>

<h2>Market exclusivity period</h2>

<p>On grant of a marketing authorisation with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication.</p>

<p>The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain.</p>

<p>The remaining market exclusivity periods for centrally authorised orphan medicine marketing authorisations granted prior to 1st January 2021 that have been  converted to Great Britain marketing authorisations will continue to apply. It is not necessary to submit orphan maintenance reports to the MHRA, but they can be provided as additional information.</p>

<p>In the UK/Great Britain there is no orphan designation issued separately from the MA. Therefore, if a Change of Ownership application is submitted, the orphan designation will automatically transfer.</p>

<h2>Paediatric indications</h2>

<p>Orphan medicines authorised in Great Britain with the results of studies from a paediatric investigation plan (PIP) included in the product information are eligible for an additional 2 years of market exclusivity.</p>

<h2>Review of market exclusivity period</h2>

<p>Regulation 58D of the Human Medicines Regulation 2012 (as amended) establishes the possibility for the UK Licensing Authority to request that the market exclusivity be reduced from 10 to 6 years, under certain circumstances, if the orphan criteria are no longer met in relation to the medicinal product.</p>

<h2>Variation applications (section 4.1 of the Summary of Products Characteristics)</h2>

<p>Marketing authorisation holders with orphan status are required to submit the <span class="attachment-inline"><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/949023/GB_Orphan_Drug_Application_Form.docx" class="govuk-link">Great Britain Orphan Drug Designation Application Form</a> (<span class="type">MS Word Document</span>, <span class="file-size">831KB</span>)</span> with their variation MA application for new or extensions to orphan therapeutic indications. The orphan criteria will be assessed in parallel to the approval of the new indication.</p>

<p>A new period of market exclusivity is only given if the applied for therapeutic indication falls within a new orphan condition.</p>

<p>For non-orphan indications, a new marketing authorisation application is required.</p>

<h2>Fees</h2>

<p>There are no additional fees to apply for orphan designation. Information on fee waivers and refunds for orphan medicines is provided in the <a href="https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees" class="govuk-link">amended MHRA application fees</a>.</p>

<h2>
<abbr title="small and medium sized enterprise">SME</abbr> status</h2>

<p>Companies who have, or intend to seek, <abbr title="small and medium sized enterprise">SME</abbr> status should ensure that they have the relevant documentation in place if an <abbr title="small and medium sized enterprise">SME</abbr> fee refund is to be applied for.</p>

<h2>Orphan register</h2>

<p>All medicines that gain an orphan marketing authorisation from the UK Licensing Authority will be listed on its <a href="https://www.gov.uk/government/publications/orphan-registered-medicinal-products" class="govuk-link">Orphan Register</a>.</p>

<p>When the period of market exclusivity for an indication ends, the orphan designation for that indication expires and is removed from the Orphan Register. The product will remain on the Orphan Register if other authorised orphan indications remain within their period of exclusivity.</p>

<p>Once all of the orphan designations associated with an approved medicine have expired or been withdrawn by the sponsor, the medicine ceases to be classified as an orphan medicine and no longer benefits from the orphan incentives. The product will be removed from the Orphan Register.</p>

<h2>Contact</h2>
<p>For further information, please email our Customer Services Centre at <a href="mailto:info@mhra.gov.uk" class="govuk-link">info@mhra.gov.uk</a> or call 020 3080 6000. You can also email <a href="mailto:orphan@mhra.gov.uk" class="govuk-link">orphan@mhra.gov.uk</a> with urgent questions. Alternatively, contact your Trade Association by emailing:</p>

<ul>
  <li>Association of the British Pharmaceutical Industry (ABPI): <a class="govuk-link" href="mailto:regulatory@abpi.org.uk">regulatory@abpi.org.uk</a>
</li>
  <li>British Generic Manufacturers Association (BGMA): <a href="mailto:info@britishgenerics.co.uk" class="govuk-link">info@britishgenerics.co.uk</a>
</li>
  <li>BioIndustry Association (BIA): <a class="govuk-link" href="mailto:regulatory@bioindustry.org">regulatory@bioindustry.org</a>
</li>
  <li>Clinical &amp; Contract Research Association (CCRA): <a href="mailto:mail@ccra.org.uk" class="govuk-link">mail@ccra.org.uk</a>
</li>
  <li>Ethical Medicines Industry Group (EMIG): <a href="mailto:info@emig.org.uk" class="govuk-link">info@emig.org.uk</a>
</li>
  <li>Health Food Manufacturers’ Association (HFMA): <a class="govuk-link" href="mailto:pennyviner@btconnect.com">pennyviner@btconnect.com</a>
</li>
  <li>The National Pharmacy Association (NPA): <a href="mailto:independentsvoice@npa.co.uk" class="govuk-link">independentsvoice@npa.co.uk</a>
</li>
  <li>
    <p>Proprietary Association of Great Britain (PAGB): <a href="mailto:regulatory@pagb.co.uk" class="govuk-link">regulatory@pagb.co.uk</a></p>

  </li>
</ul>
</div>

</div>

      <div class="responsive-bottom-margin">
        <div lang="en" data-module="toggle" class="app-c-published-dates app-c-published-dates--history">
    Published 31 December 2020
    <br>Last updated 22 February 2021
      <a data-expanded="false" class="app-c-published-dates__toggle govuk-link" href="#full-history" data-toggled-text="-&nbsp;hide all updates" data-controls="full-history">+&nbsp;show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2021-02-22T15:00:01.000+00:00">22 February 2021</time>
              <p class="app-c-published-dates__change-note">Added new information about the application process for products with an orphan designation, on how a review of market exclusivity period would work and on the orphan register.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time datetime="2021-02-09T14:30:07.000+00:00" class="app-c-published-dates__change-date timestamp">9 February 2021</time>
              <p class="app-c-published-dates__change-note">Added a link to the Orphan register.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-12-31T23:01:00.000+00:00">31 December 2020</time>
              <p class="app-c-published-dates__change-note">First published.</p>
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element="" class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg width="13" height="17" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 13 17" class="app-c-back-to-top__icon">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
    
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
  </div>
  
<div class="govuk-grid-column-one-third">
  


</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav class="gem-c-related-navigation__nav-section" role="navigation" data-module="gem-toggle">

    <h2 class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul data-module="track-click" class="gem-c-related-navigation__link-list">


        <li class="gem-c-related-navigation__link"><a href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-options="{&quot;dimension28&quot;:&quot;1&quot;,&quot;dimension29&quot;:&quot;Marketing authorisations, variations and licensing guidance&quot;}" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>


    </main>